Bhattacharya provides calm answers to anxious questions at confirmation hearing Trump nominee for NIH director calls for transparency, audits of indirect costs

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

Our Hispanic community is a vibrant and essential part of the American tapestry, contributing richly to the country’s society, culture, and economy. Yet, when it comes to healthcare, this community grapples with significant disparities, especially in cancer care.

George Sigounas named the first-ever chief science advisor at NCI

George Sigounas, an expert in bone marrow transplantation, was named to the newly created post of chief science advisor at NCI.

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Clairity Inc. received FDA De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025—propelling a new era of precision medicine in breast cancer.

June 06, 2025

Vol.51 No.22

Cancer Policy

Prasad’s stricter FDA policy for COVID-19 vaccines could limit future access

FDA—under the leadership of cyber-iconoclast and new director of the agency’s Center for Biologics Evaluation and Research, Vinay Prasad—is taking a new approach to COVID-19 vaccines.

May 23, 2025

Vol.51 No.20

By Claire Marie Porter

Podcast The Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.

May 16, 2025

Vol.51 No.19

By Jacquelyn Cobb and Claire Marie Porter

Bhattacharya provides calm answers to anxious questions at confirmation hearing

Trump nominee for NIH director calls for transparency, audits of indirect costs

YOU MAY BE INTERESTED IN

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

George Sigounas named the first-ever chief science advisor at NCI

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Prasad’s stricter FDA policy for COVID-19 vaccines could limit future access

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

Renew today!

Subscriber content

Never miss an issue!

Login

Bhattacharya provides calm answers to anxious questions at confirmation hearing

Trump nominee for NIH director calls for transparency, audits of indirect costs

YOU MAY BE INTERESTED IN

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

George Sigounas named the first-ever chief science advisor at NCI

Clairity becomes the first FDA-authorized AI platform for breast cancer prediction

Prasad’s stricter FDA policy for COVID-19 vaccines could limit future access

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFsTo avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges